Small Molecules

11 Jan 2018 Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
10 Jan 2018 Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation
09 Jan 2018 GT Biopharma Announces Completion of Dosing in Phase 1 Clinical Trial of GTP-004 for Myasthenia Gravis
09 Jan 2018 CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
09 Jan 2018 GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
09 Jan 2018 BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC
09 Jan 2018 pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA
09 Jan 2018 ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial
09 Jan 2018 Infinity Provides Update on IPI-549 Phase 1/1b Study, 2018 Goals and Financial Guidance
09 Jan 2018 TopiVert Pharma Limited: Positive results from TOP1288 Phase 1 study
09 Jan 2018 FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection
09 Jan 2018 Eisai and Merck & Co., Inc., Kenilworth, N.J., USA. Receive Breakthrough Therapy Designation from U.S. FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Carcinoma
09 Jan 2018 MEI Pharma Announces FDA Clearance of IND Application for CDK Inhibitor Voruciclib
09 Jan 2018 Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
09 Jan 2018 AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis
08 Jan 2018 Semnur Pharmaceuticals Begins Pivotal Phase 3 Trial For SP-102 In Patients With Lumbar Radicular Pain/Sciatica
08 Jan 2018 Positive topline results with GLPG1972 in osteoarthritis patients
08 Jan 2018 Saniona AB: Saniona reports top line results from the Tesomet Phase 2a interim study in Prader-Willi syndrome
08 Jan 2018 Successful completion of pre-clinical safety studies with MIV-818, enabling start of phase I clinical studies in 2018
05 Jan 2018 Ohr Pharmaceutical Announces Efficacy Results from the MAKO Study in Wet-AMD
05 Jan 2018 BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva
04 Jan 2018 Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis
04 Jan 2018 Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study)
04 Jan 2018 Asana BioSciences Announces Achievement of Positive Results in the Clinical Proof of Concept Study in Atopic Dermatitis with ASN002, A Novel Oral JAK/SYK Inhibitor
04 Jan 2018 Cortexyme Initiates Phase 1 Clinical Development of COR388, a Promising Potential Treatment for Alzheimer’s and Other Degenerative Diseases

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top